WAT News and Press, Waters Corporation From 08/02/22

Highlights Sales of $714 million grew 5% as reported and 10% in constant currency Continued strong momentum as instrument sales grew 12% in constant currency, with double-digit growth across LC, MS and TA product lines Broad-based performance across all end-m...

Waters ( NYSE: WAT ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. EPS Estimate is $2.67 (+2.7% Y/Y) and the consensus Revenue Estimate is $706.77M (+3.7% Y/Y). has beaten EPS estimates 100% of the time and has beaten revenue esti...

News Summary: Waters is providing both technology and expertise to help advance the science of plant-based proteins and tackle problems of climate change and food security Waters joins the Plant Protein Innovation Center at the University of Minnesota to collaborate with m...

Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...

Fundsmith Equity Fund manages £22.6 billion on behalf of some of the world’s largest and most sophisticated wealth managers and private banks, as well as for prominent families, charities, endowments and individuals invested in our fund range, and is focused on delivering supe...

Waters Corporation (NYSE:WAT) will hold its Q2 2022 financial results conference call live on Tuesday, August 2 nd 2022 at 8:00 a.m. eastern time. A live webcast of the presentation will be available on Waters’ investor relations website at https://ir.waters.com . A r...

Fundsmith’s 13F portfolio value decreased from $40.98B to $29.12B this quarter. They added Adobe and Mettler-Toledo while almost selling out Johnson & Johnson. The top three positions are Microsoft, IDEXX Labs, and Estee Lauder, and they add up to ~23% of the portfolio....

West Pharmaceutical Services has performed extraordinarily well in recent years. The future of the enterprise looks bright and the company will likely continue to fare well in the years to come. But given how pricey shares are today, buying it won't make sense to a lot of investor...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

For investors who have been waiting to buy shares in Agilent, this is probably a good time to buy at least a starter position. For the last couple of years, Agilent had traded above what fundamentals justified, and now finally shares are priced to deliver very decent 8-9% returns. ...